Discover
Rare Discussions
Rare Discussions
Author: CheckRare Editors
Subscribed: 12Played: 65Subscribe
Share
© Yes
Description
Conversations with the leaders advancing rare disease care.
Rare Discussions is CheckRare's flagship interview podcast featuring conversations with leading physicians, researchers, patient advocates, and industry experts. These episodes explore advances in diagnosis, treatment, research, and patient care across the rare disease landscape.
Whether highlighting groundbreaking therapies or sharing expert clinical perspectives, Rare Discussions highlights the experts who are shaping the future of rare disease medicine.
Rare Discussions is CheckRare's flagship interview podcast featuring conversations with leading physicians, researchers, patient advocates, and industry experts. These episodes explore advances in diagnosis, treatment, research, and patient care across the rare disease landscape.
Whether highlighting groundbreaking therapies or sharing expert clinical perspectives, Rare Discussions highlights the experts who are shaping the future of rare disease medicine.
214 Episodes
Reverse
Laura Hameed, Chief Executive Officer, and Dominique Pichard, MD, MS, Chief Scientific and Medical Officer of the International Rett Syndrome Foundation (IRSF), discuss the changing treatment landscape for Rett syndrome and the organization’s commitment to supporting patients and their families.Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.
Steven Ing, MD, Professor of Clinical Medicine in the Division of Endocrinology, Diabetes and Metabolism at The Ohio State University Wexner Medical Center, discusses three-year real-world findings from an interim analysis of the XLH Disease Monitoring Program (DMP) comparing burosumab with conventional therapy in adults with X-linked hypophosphatemia (XLH).Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.
Positive final efficacy results from the phase 3 ORIGIN 3 trial, evaluating Trutakna (atacicept) in adults with primary IgA nephropathy (IgAN) at risk of disease progression. Marshall Fordyce, MD, founder and CEO of Vera Therapeutics, discusses the findingsRare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.
A poster analysis of the phase 3 ADVANCE OUTCOMES trial, presented at the CHEST 2026 Annual Meeting in Phoenix, Arizona, found that oral ralinepag reduced clinical worsening across different baseline risk profiles in patients with pulmonary arterial hypertension (PAH).Jean Elwing, MD, FCCP, Professor of Clinical Internal Medicine at the University of Cincinnati, discusses the findings and their implications for PAH treatment. Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.
Parth Rali, MD, MBBS, FCCP, pulmonologist at Temple Health, discusses interim findings from the PHINDER study evaluating pulmonary hypertension (PH) screening strategies in patients with interstitial lung disease (ILD).Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.








